Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of HLX15-IV versus DARZALEX with lenalidomide-dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
CTR20250806Phase 3Terminated
- Sponsor
- HyBioPharma
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of HLX15-IV in multiple myeloma (MM), sponsored by HyBioPharma. Started Mar 2025; status: terminated.
02
Drugs
HLX15-IV
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20250806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250806.